Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 10/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2761914 | 0.95 | TAAR1 (0.56) | HTR2ATAAR1CYP3A4HTR2C | |
| SCHEMBL26133654 | 0.90 | HTR2A (0.50) | HTR2ATAAR1CYP3A4CYP19A1HTR2C | |
| SCHEMBL23836672 | 0.84 | TAAR1 (0.60) | HTR2ATAAR1HTR2CKDM4EALDH1A1 | |
| SCHEMBL19882731 | 0.84 | POLB (0.48) | HTR2ATAAR1CYP3A4CYP19A1HTR2C | |
| SCHEMBL13153774 | 0.82 | TAAR1 (0.72) | HTR2ATAAR1HTR2CKDM4EALDH1A1 | |
| SCHEMBL1398131 | 0.81 | GAA (0.45) | HTR2ATAAR1CYP3A4CYP19A1HTR2C | |
| SCHEMBL29364056 | 0.81 | TAAR1 (0.77) | HTR2ATAAR1CYP19A1HTR2C | |
| SCHEMBL1253319 | 0.81 | TAAR1 (0.77) | HTR2ATAAR1CYP19A1HTR2C | |
| Hydrochloric Acid SCHEMBL3101245 | 0.81 | TAAR1 (0.70) | HTR2ATAAR1HTR2CKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL20445976 | 0.81 | TAAR1 (0.59) | HTR2ATAAR1HTR2CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023858-B2 | Substituted pyrido[2,3-d]pyrimidines as delta-5-desaturase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-05 | — | — | US | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
| EP-2430036-B1 | SUBSTITUTED 6-(BENZYLAMINO) PURINE RIBOSIDE DERIVATIVES, USE THEREOF AND COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2014-07-30 | — | — | EP | disclosed |
| US-20140066394-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | BIOPATTERNS, S.R.O (CZ) | 2014-03-06 | — | — | US | disclosed |
| EP-2597095-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2013-05-29 | — | — | EP | disclosed |
| US-20130131050-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-23 | — | — | US | disclosed |
| CN-103119043-A | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL | 2013-05-22 | — | — | CN | disclosed |
| US-20120071433-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2012-03-22 | — | — | US | disclosed |
| CN-101300012-B | Use of Diaminopyrimidine as P2X3 and P2x2/3 modulators in preparing medicine for treating respiratory diseases | HOFFMANN LA ROCHE | 2011-09-14 | — | — | CN | disclosed |
| CN-101300012-A | Diaminopyrimidine as P2X3 and P2x2/3 modulators | ROCHE PALO ALTO LLC (CH) | 2008-11-05 | — | — | CN | disclosed |
| US-20060205673-A1 | 2-Amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives | FURET PASCAL | 2006-09-14 | — | — | US | disclosed |
| EP-1290012-B1 | 2-AMINO-3-HYDROXY-4-TERT-LEUCYL-AMINO-5-PHENYL-PENTANOIC ACID AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2006-05-10 | — | — | EP | disclosed |
| US-20030166572-A1 | 2-Amino-3-hydroxy-4-tert-leucyl-amino-5 phenyl-pentanoic acid amide derivatives | FURET PASCAL (FR) | 2003-09-04 | — | — | US | disclosed |
| EP-1290012-A2 | 2-AMINO-3-HYDROXY-4-TERT-LEUCYL-AMINO-5-PHENYL-PENTANOIC ACID AMIDE DERIVATIVES | Novartis AG (CH) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001089282-A2 | 2-AMINO-3-HYDROXY-4-TERT-LEUCYL-AMINO-5-PHENYL-PENTANOIC ACID AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066394-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | PNP, NUDT1, TYMP | HTR2A 2455/4885TAAR1 4462/4885CYP3A4 4358/4885 |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | HTR2A 3798/4885TAAR1 4348/4885CYP3A4 4016/4885 |
| US-20030166572-A1 | 2-Amino-3-hydroxy-4-tert-leucyl-amino-5 phenyl-pentanoic acid amide derivatives | AADAT, ABAT, TTR | HTR2A 709/4885TAAR1 845/4885CYP3A4 756/4885 |
| US-20120071433-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | CD38, NUDT1, PNP | HTR2A 2574/4885TAAR1 4434/4885CYP3A4 4487/4885 |
| US-20060205673-A1 | 2-Amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives | AADAT, ABAT, ALB | HTR2A 854/4885TAAR1 922/4885CYP3A4 784/4885 |
| US-20130131050-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | LTB4R2, LTB4R, LTC4S | HTR2A 2833/4885TAAR1 1408/4885CYP3A4 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.